Raymond James Downgrades Audentes Therapeutics (BOLD) to Market Perform Following Acquisition
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse downgraded Audentes Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
